

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b>  <b>A61K 9/64</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 91/16887</b> <b>(43) International Publication Date:</b> 14 November 1991 (14.11.91)
<b>(21) International Application Number:</b> PCT/US91/02842 <b>(22) International Filing Date:</b> 1 May 1991 (01.05.91)  <b>(30) Priority data:</b> 517,340 1 May 1990 (01.05.90) US  <b>(71) Applicant:</b> RESEARCH TRIANGLE INSTITUTE [US/US]; Office of Research Contracts, Cornwallis Road, Hanes Building, Research Triangle Park, NC 27709 (US).  <b>(72) Inventors:</b> SCHINDLER, Anton ; 3742 Bentley Drive, Durham, NC 27707 (US). HOLLOMON, Martha, G. ; 115 Charter Courter, Colonial Townes, Cary, NC 27511-5095 (US).		<b>(74) Agents:</b> KELBER, Steven, B. et al.; Oblon, Spivak, McClelland, Maier & Neustadt, Crystal Square Five-Fourth Floor, 1755 South Jefferson Davis Highway, Arlington, VA 22202 (US).  <b>(81) Designated States:</b> AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CI (OAPI patent), CM (OAPI patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (European patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL (European patent), NO, RO, SD, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> BIODEGRADABLE POLYESTERS FOR SUSTAINED DRUG DELIVERY  <b>(57) Abstract</b>  Random copolymers of caprolactone containing 5-25 mole-% trimethylene carbonate are shaped into tubular devices to form cylindrical capsules to be used for the sustained delivery of drugs after subcutaneous implantation in humans or animals.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

-1-

DescriptionBiodegradable Polyesters For Sustained Drug DeliveryTechnical Field

The present invention relates to novel polymer-drug  
5 formulations possessing improved drug permeabilities.  
More specifically, this invention relates to random  
copolymers of caprolactone and trimethylene carbonate  
(1.3-dioxane-2-one) possessing high molecular weight, and  
the use of said copolymers for the fabrication of a  
10 biodegradable, tubular device in the form of a  
cylindrical capsule useful for the sustained delivery of  
drugs after subcutaneous implantation of said device in  
humans or animals.

Background Art

15 U.S. Patents 4,243,775 and 4,300,565 to Rosensaft et al  
disclose a procedure of sequential monomer addition to  
form partially ordered copolymers composed predominantly  
of glycolide in combination with other cyclic ester  
monomers such as trimethylene carbonate to be used for  
20 the fabrication of surgical articles, particularly  
sutures. U.S. Patent 4,429,080 to Casey et al discloses  
the fabrication of triblock copolymers possessing  
trimethylene carbonate center blocks to be used for the  
production of surgical articles, particularly sutures and  
25 ligatures. U.S. Patents No. 4,788,979 and 4,791,929 to  
Jarrett et al disclose the production of low molecular  
weight copolymers of caprolactone and trimethylene  
carbonate to be useful as bioabsorbable coatings of  
surgical articles such as sutures. All of these patents  
30 do not, however, disclose the concept of using random  
copolymers of high molecular weight to provide drug  
formulation for the sustained subdermal delivery of  
drugs.

-2-

U.S. Patent No. 4,503,216 to Fagerburg et al discloses the reaction of poly(caprolactone) with ethylene carbonate to produce difunctional hydroxyl-terminated polyether-esters useful as liquid urethane forming polyols. U.S. Patent 4,810,775 to Bendix et al discloses a process relating to the purification of polyesters, particularly resorbable polyesters, by precipitating the polymers under the effect of high shear forces. Both patents do not disclose the concept of sustained drug delivery devices.

U.S. Patent 3,887,699 to Volles discloses a device for dispersing drugs from a biodegradable polymeric material which is shown to be polylactate. U.S. Patent 4,148,871 to Pitt et al discloses the use of biodegradable homopolymers and copolymers of caprolactone for formulating devices to accomplish the sustained subdermal delivery of drugs. The patent does not disclose the fabrication or the use of devices incorporating trimethylene carbonate.

U.S. Patent No. 4,702,917 to Schindler discloses the use of homopolymers of caprolactone and of its copolymers with other lactones in combination with aliphatic polyethers to formulate tubular drug delivery devices possessing walls of defined porosity, particularly useful for the delivery of hydrophilic compounds such as polypeptides. The patent does not disclose the fabrication or the use of devices which incorporate trimethylene carbonate and which possess a dense, non-porous wall.

-3-

Disclosure of the Invention

The present invention relates to biodegradable, sustained drug delivery devices for subcutaneous implantation, said devices being fabricated from random copolymers of caprolactone and trimethylene carbonate inside a narrow compositional range, and said devices providing higher drug release rates than obtainable with similar devices described in the prior art. The higher drug release rates achieved with devices of this invention permits the use of smaller devices than possible according to the prior art, said devices still providing the required therapeutical levels of released drug but with a concomitant improvement in comfort to the patient and a reduction in the body burden during bioadsorption of said device after exhaustion of the contained drug. It was found that cylindrical, tubular devices, possessing good mechanical strength and formstability, could be produced from a random copolymer containing trimethylene carbonate and caprolactone in a mole ratio of about 1:5, said devices exhibiting drug release rates for levonorgestrel being three times the drug release rates of polycaprolactone devices of identical geometric form and dimension.

The present invention addresses the formulation of a bioabsorbable pharmaceutical device for subdermal administration, designed to release effective amounts of drug during a predetermined time period. The drug delivery device of this invention is composed of a drug core surrounded by a polymer shell in the form of a short, cylindrical tube with both ends sealed to form a capsule which can be administered by means of a trocar. The term drug is therein to be understood as defined in the Federal Food, Drug, and Cosmetic Act, Section 201(2)g. Specifically mentioned drugs may include among

-4-

others: steroidal and nonsteroidal contraceptive agents, male and female hormones, narcotics and narcotic antagonists, as well as antineoplastic and anti-inflammatory agents. The dense, non-porous structure of the capsule wall requires drugs which are soluble to some extent in the polymer wall and excludes most drugs of strongly hydrophilic nature.

The drug delivery device of the present invention belongs to the category of implantable reservoir devices, a category which encompasses devices where the drug is contained inside a surrounding polymer shell which represents the reservoir and acts as a barrier controlling the release of the drug from the implanted device into the surrounding tissue. The rate at which the drug is released from the device is governed by the permeability of the polymer shell for the drug under consideration which, in turn, depends on the product of two material constants characteristic for a given polymer-drug combination, namely, the diffusivity and the solubility of the drug in the polymer it is combined with. Both material constants are strongly affected by the morphology of the polymer, particularly its degree of crystallinity, insofar as both the dissolution of the drug in the polymer shell and its diffusive transport through the polymer shell take place exclusively in the amorphous phase of the polymer. Consequently, a decrease of the crystallinity of the polymer causes an increase of both the solubility and the diffusivity of the drug, resulting in an increase of the permeability of the device and a correspondingly higher drug delivery rate.

In an alternative embodiment, an implantable sustained delivery device may comprise the copolymer in matrix form, defining an intimate mixture of drug and copolymer. Preferably, such implants are cylindrical or spherical in shape.

-5-

The desirable increase of the drug permeability of a reservoir device attained by decreasing the crystallinity of its polymeric shell finds its limitation in the loss of formstability of the device accompanying low  
5 crystallinity contents. Polymers useful as reservoir devices for sustained drug delivery systems need to have glass transition temperatures below body temperature to assure sufficiently high diffusivity and solubility of the drugs. The formstability of such devices is then  
10 assured by the presence of physical crosslinks in form of crystalline domains; with excessive loss of the latter the formstability is lost too.

#### Brief Description of the Invention

The Figure illustrates the effect of the  
15 trimethylene carbonate content of copolymers with caprolactone on the specific release rate of levonorgestrel (in  $\mu\text{g}/\text{cm}\cdot\text{day}$ ) from cylindrical capsules fabricated from these copolymers and possessing 2.4 mm outer diameter and different wall thicknesses in the  
20 range of 0.10. 3 mm.

#### Best Mode For Carrying Out The Invention

According to the present invention, the polymer shell of the device consists of a random copolymer of caprolactone with trimethylene carbonate containing not  
25 less than 5 and not exceeding 25 mole-% of trimethylene carbonate, the preferred compositional range being 10-20 mole-%. In this embodiment of the invention the term random copolymer means the result of a copolymerization reaction utilizing intimately mixed comonomers by  
30 charging into the reactor a solution of trimethylene carbonate in caprolactone. Under this condition a random

-6-

distribution of both comonomer units in the polymer chain results although variations in reaction conditions can affect to some extent the degree of randomness of the comonomer distribution.

5 Surprisingly, optimal properties concerning the required combination of formstability, mechanical strength, and drug permeability are observed only with drug delivery devices fabricated from copolymers with compositions inside the narrow range of 10-20 mole-%  
10 trimethylene carbonate contents. Devices utilizing copolymers with compositions outside the indicated range of 10-20 mole-% trimethylene carbonate contents are deficient in some of the properties in comparison to copolymers with compositions inside the indicated optimal  
15 range. Copolymers containing less than 10 mole-% trimethylene carbonate, although possessing good mechanical properties, are limited in their drug permeabilities which do not exceed that of polycaprolactone by more than 50%. Copolymers with  
20 trimethylene carbonate values exceeding the optimal compositional range are of increasingly lower crystallinities and, consequently, lack the required formstability. Indeed, the formstability of devices fabricated from copolymers exceeding a trimethylene  
25 carbonate content of 25 mole-% is so low to preclude permeability determinations to be performed.

In Table 1 are summarized mechanical properties of three copolymers, COP-1-, -11 and -12, possessing trimethylene carbonate contents of 11.3, 16.5 and 21.9  
30 mole-%, respectively, together with the corresponding properties of polycaprolactone, designated PCL, for comparison. The data were obtained at ambient temperature on compression molded films of about 0.3 mm thickness utilizing an Instron Universal Testing Machine,  
35 Model 112. Inside the compositional range of interest



-7-

all of the determined mechanical properties of the copolymers were found to be linearly dependent on their trimethylene carbonate contents. The relevant linear relations are as follows wherein the expression (TMC) represents the trimethylene carbonate content of the copolymers expressed in mole-%:

Young's Modulus (MP2)	= 259.1 - 8.18 (TMC)
Yield Stress (MP2)	= 16.2 - 0.522 (TMC)
Nominal Stress at Break (MP2)	= 30.7 - 0.605 (TMC)
10 Draw Ratio at Break	= 8.22 + 0.557 (TMC)

Inside the optimal compositional range, the caprolactone-trimethylene carbonate copolymers combined a surprisingly high tensile strength with exceptionally high draw ratios. This combination of properties is especially advantageous for the intended use of the copolymers as subcutaneous drug delivery implants since these properties reduce the likelihood of rupture of a device during use or during surgical removal if indicated.

20 In Table 2 are presented the crystallinity contents and the melting points of caprolactone-trimethylene carbonate copolymers together with the permeabilities for levonorgestrel of drug delivery devices fabricated from several of these copolymers including polycaprolactone.

25 Crystallinity contents and melting points were determined by differential scanning calorimetry utilizing Perkin-Elmer equipment, Model DSC-2 with thermal data station. The permeability values for levonorgestrel were derived from in vitro drug release studies performed in

30 water at 37.5°C Polymer tubes of about 2.0 cm length, 2.1 2.6 mm outer diameter, and wall thicknesses in the range of 0.1 0.3 mm were filled with about 15 - 20 mg dry, micronized drug and heat sealed at both ends. The

-8-

resulting capsules were kept submerged in 200 ml water contained in 500 ml Erlenmeyer flasks, thermostated at 37°C under mild rotary shaking. The released drug was monitored spectrophotometrically at 240 nm.

5       The permeabilities of copolymers of different compositions for levonorgestrel were derived from measurements of the steady state release rates and device dimensions. The steady state release of a drug from a cylindrical reservoir device into a perfect sink is given  
10    by

$$Q/t = [2\pi/\ln(R/r)]DC$$

where Q is the amount of drug released during the time interval t, R and r are the outer and the inner radius of the device, respectively, D is the diffusion constant,  
15    and C is the solubility of the drug in the polymer. The product DC is the permeability, expressed  $\mu\text{g}/\text{cm}\cdot\text{day}$ , which is a material constant characterizing the release system for a specific polymer-drug combination.

Permeability data for levonorgestrel in combination  
20    with trimethylene carbonate-caprolactone copolymers of different compositions are presented in the last column of Table 2. These data demonstrate the improvement in drug release performance resulting from the incorporation of an increasing number of trimethylene carbonate units  
25    in the polycaprolactone chain. A trimethylene carbonate content slightly exceeding 10 mole-% already doubles the release performance of polycaprolactone and a fourfold increase over the polycaprolactone performance is  
30    obtained with a random copolymer containing about 22 mole-% trimethylene carbonate.

Inside the compositional range from zero to about 22 mole-% trimethylene carbonate content the permeabilities of the copolymers for levonorgestrel can be described by

-9-

a second order parabola of the form

$$\text{Permeability} = 0.251 + 0.00113 (\text{TMC}) + 0.00135 (\text{TMC})^2$$

where (TMC) represents the mole-% trimethylene carbonate units in the copolymer. Utilizing this equation, release rates of levonorgestrel in  $\mu\text{g}/\text{cm}\cdot\text{day}$  can be calculated for cylindrical capsules possessing any outer diameter and wall thickness and being fabricated from random copolymers of trimethylene carbonate and caprolactone of any composition inside the range from zero to 20.0 mole-% trimethylene carbonate content. As an example, results of such calculations are presented in the attached Figure for capsules possessing an outer diameter of 2.4 mm and varying wall thickness.

The data of Table 2 demonstrate the surprisingly narrow compositional range suitable for the fabrication of implantable drug delivery devices possessing improved release properties. Up to 5% trimethylene carbonate content the permeability of a device increases by less than 10% over that of a device derived from polycaprolactone and even up to a trimethylene carbonate content of 10% the permeability increase of the device remains below 50%. Significant increases in permeability of more than 50% are observed with devices containing more than 10% trimethylene carbonate, and at 20 mole-% trimethylene carbonate content the copolymers exhibit three times the permeability of polycaprolactone. At the latter trimethylene carbonate content the crystalline melting point of the copolymer already approaches body temperature thus precluding to further increase the permeability of the devices by increasing their trimethylene carbonate contents.

TABLE 1

Effect of Trimethylene Carbonate Content on the Mechanical Properties of Random  
Copolymers of Caprolactone With Trimethylene Carbonate

Copolymer Number	Mole-% Trimethylene Carbonate	Young's Modulus (MPa)	Yield Stress (MPa)	Nominal Stress at Break (MPa)	Draw Ratio at Break
PCL	0.0	252	15.9	31.3	9.5
COP-10	11.3	184	10.8	22.3	14.5
COP-11	16.5	119	8.1	21.1	16.5
COP-12	21.9	75	4.2	17.9	22.5

-11-

TABLE 2

Effect of Composition on Crystallinity, Crystalline Melting Temperature,  
and Permeability for Levonorgestrel of Random Copolymers of Caprolactone  
With Trimethylene Carbonate

Copolymer Number	Mole-% Trimethylene Carbonate	Crystallinity Content (%)	Melting Temperature (°C)	Permeability ( $\mu\text{g}/\text{cm}\cdot\text{day}$ )
PCL	0.0	51.3	58.7	0.251
COP-5	10.3	38.3	50.7	---
COP-10	11.3	36.3	47.3	0.449
COP-6	15.6	32.3	46.3	0.559
COP-11	16.5	26.4	45.7	0.680
COP-7	18.7	29.2	44.3	---
COP-1	19.7	24.2	41.1	0.704
COP-12	21.9	21.8	41.2	1.000
COP-8	23.6	20.8	39.2	---
COP-2	30.1	13.1	37.0	---

-12-

The preparation of a drug delivery device relating to this invention is performed by preparing a random copolymer of caprolactone and trimethylene carbonate of desired composition, followed by transforming said  
5 copolymer into tubular shape, and finally fabricating drug filled capsules from said copolymer tubing.

The copolyesters of this invention are random copolymers of trimethylene carbonate and caprolactone in the compositional range of 5-25 mole-% trimethylene  
10 carbonate, preferably insider the range of 10-20 mole-% trimethylene carbonate. Caprolactone is a commercially available compound and trimethylene carbonate can be prepared as disclosed in the literature (W. H. Carothers and F. J. can Natta, J. Am. Chem. Soc., 52, 314  
15 (1930) so that neither the compounds per se nor the method by which they are obtained constitutes any portion of the invention. The random copolymers are prepared by polymerizing a solution of trimethylene carbonate in caprolactone at elevated temperatures utilizing tin salts  
20 as catalysts in amounts of 100-500 ppm. The polymerization temperature can be in the range of 100-180°C, the preferred temperature range being 120-140°C. The tin salts preferentially used as polymerization catalysts are stannous octoate  
25 (2-ethyl-hexanoate) or stannous chloride although other tin salts can be used in amounts according to their catalytic activity. By utilizing carefully purified monomers and working under stringent exclusion of humidity high molecular weight random copolymers with  
30 intrinsic viscosities in chloroform exceeding 1.5 dl/g are obtained at better than 99% conversion as is well known to those skilled in the art. The transformation of the copolymer into tubular shape of the desired geometric dimension can be accomplished by conventional methods

-13-

such as injection molding, dip casting, or extrusion utilizing screw or ram extruders.

During the last step of the process, the drug containing capsules are fabricated by filling required  
5 lengths of the copolymer tubing with the drug and subsequently heat sealing the tube ends. Preferentially, the drug is introduced in the form of a dry, micronized powder but mixtures of drug with a dispersing agent are also applicable. A dispersing agent of volatile nature  
10 may be added to the drug to facilitate the filling process, said dispersing agent being completely removed by evaporation prior to completely sealing the capsule. Non-volatile dispersing agents which remain in the sealed capsule together with the enclosed drug may also be used  
15 but under these conditions the permeability of the device may differ considerably from that of an identical device prepared in the absence of the dispersing agent. The kind and amount of drug, the dimension of the device, and the presence or absence of a dispersing agent may be  
20 chosen in accordance with the selected copolymer composition to provide optimal drug delivery conditions for the particular therapeutic application under consideration. Particularly, the composition of the random copolymer of caprolactone and trimethylene  
25 carbonate together with the geometric dimensions of the fabricated capsule will be decisive for the obtainable rate of the drug release.

The rate at which the polymeric device is degraded within the body is determined by the composition of the  
30 device as well as the mode of administration to the patient. Polycaprolactone has a halflife time of about nine months, i.e., during this time period the molecular weight of the polymer decreases to half its initial value. Copolymers with increasing trimethylene carbonate  
35 contents possess corresponding shorter halflife times.

-14-

The following examples are offered to more fully illustrate the invention, but are not to be construed as limiting the scope thereof.

EXAMPLE 1:

5       A solution of 3.3 g trimethylene carbonate in 15 g caprolactone and containing 50 ppm stannous octoate was charged to a glass vial equipped with a sealing capillary. The vial contents were degassed, the vial was sealed off, and then placed into a circulating air oven  
10       thermostated at 140°C. After 46 hours a completely colorless and high viscous polymer had formed which was removed with a spatula. The conversion was better than 99% according to the thermogravimetric analysis of the as-formed copolymer which indicated a weight loss of only  
15       0.52% at 220°C. The intrinsic viscosity of the copolymer in chloroform at 30°C was 2.64 dl/g. The copolymer is designated COP-1 in Table 2.

      A thin film, cast from chloroform solution, was rolled on a tubular Teflon support and then annealed at  
20       80°C under vacuum. The resulting tube had an outer diameter of 2.276 nun and a wall thickness of 0.240 mm. Two capsules were prepared of 2.0 cm length which were filled with 16.7 and 11.1 mg of dry, micronized levonorgestrel. The capsules were kept submerged in 200  
25       ml deionized water under mild shaking at 37.5°C. The water was exchanged three times a week and released drug was monitored spectrophotometrically at 240 nm utilizing a cell with 4 cm path length. Constant release rates of 18.9 and 18.6 µg/cm.day, respectively, were observed over  
30       a time period of 212 days.

      A third copolymer capsule of the same dimensions as the previous ones and filled with 16.5 mg of dry, micronized levonorgestrel was implanted subcutaneously in



-15-

the dorsal region of an adult female New Zealand white rabbit. Blood samples were collected three times per week and the serum level of levonorgestrel was determined by radioimmunoassay. During an observation period of 90 days of means serum level of levonorgestrel was 740 pg/ml with a standard error of 26 pg/ml.

EXAMPLE 2:

450 g caprolactone containing 200 ppm stannous octoate were charged to a stainless steel reactor consisting of a stainless steel tube closed with Teflon plugs carrying o-rings and being secured by stainless steel caps. The reactor was kept in a circulating oven thermostated at 160°C for 24 hours. The polymer melt was extruded under nitrogen pressure in the form of a wire of about 3 mm diameter which was subsequently pelletized. According to thermal gravimetric analysis the conversion was better than 99.1%. The intrinsic viscosity of the polymer in chloroform was found to be 1.76 dl/g. Further data on this polymer are included in Tables 1 and 2 under the designation PCL. The pellets were fed to a screw extruder (Killion, Model KL-100) equipped with a tubing die. At a draw ratio of about 3:1 the final tube dimensions were 2.340 mm outer diameter with a wall thickness of 0.155 mm.

Two capsules of 2.5 cm length, loaded with 50.9 and 54.4 mg of dry, micronized levonorgestrel, and heat sealed on both ends were prepared for in vitro release studies. Utilizing deionized water as the release medium at 37.5°C, the release rate averages over a time period of 277 days were 11.4 and 10.8 µg/cm.day with standard errors of 0.21 and 0.34 µg/cm.day, respectively.

Two identically prepared capsules but loaded with 18.3 and 13.4 mg of dry, micronized levonorgestrel were

-16-

implanted subcutaneously in the dorsal region of an adult female New Zealand white rabbit. Blood samples were collected three times per week and the serum level of levonorgestrel was determined by radioimmunoassay.

- 5 During an observation period of 83 days the mean serum levels of levonorgestrel were 239 and 210 pg/ml with a standard errors of 11 and 13 pg/ml, respectively. These serum levels were only about one third of the serum level observed with the copolymer device described in Example 1  
10 although the copolymer device had twice the wall thickness of the polycaprolactone devices.

EXAMPLE 3:

- A copolymer was prepared according to Example 1 but utilizing 5.4 g trimethylene carbonate dissolved in 14 g  
15 caprolactone. The colorless copolymer had an intrinsic viscosity in chloroform of 1.45 dl/g. Both the melting point and the crystallinity content of the copolymer were too low for the fabrication of a drug release device. The copolymer is designated COP-2 in Table 2.

20 EXAMPLE 4:

- A copolymer was prepared according to Example 1 but utilizing 1.03 g trimethylene carbonate dissolved in 10 g caprolactone. Thermogravimetric analysis revealed a weight loss of 0.89 at 220°C. The intrinsic viscosity of  
25 the copolymer in chloroform was 1.65 dl/g. The copolymer is designated COP-5 in Table 2.

- A cylindrical capsule with 2.4 mm outer diameter and a wall thickness of 0.200 mm was prepared as in Example 1 and filled with dry, micronized norethindrone. The  
30 average in vitro release rate was found to be 46  $\mu\text{g/cm.day}$  over a release period of 90 days.

-17-

EXAMPLE 5:

A copolymer utilizing 1.65 g trimethylene carbonate dissolved in 10 g caprolactone was prepared as described in Example 1. The conversion was better than 99.8% according to a weight loss of only 0.18 at 180°C. The intrinsic viscosity in chloroform was 1.74 dl/g. The copolymer is designated COP-6 in Table 2.

A cylindrical capsule of 2.3 cm length was prepared from a rolled film with an outer diameter of 2.139 mm and a wall thickness of 196 mm. The capsule was filled with 17.4 mg of dry, micronized levonorgestrel and sealed. The in vitro release rate averaged over 130 days was found to be 17.4 µg/cm.day with a standard error of 0.71 µg/cm.day.

15 EXAMPLE 6:

The procedure of Example 2 was repeated with incorporation of the following changes. The stainless steel reactor was charged with a solution of 51.9 g trimethylene carbonate dissolved in 454.6 g caprolactone and containing 500 ppm stannous octoate. The polymerization conditions were 120°C for 51 hours followed by 140°C for 16 hours. The conversion was better than 99.3% according to a weight loss of only 0.65% at 220°C. The intrinsic viscosity in chloroform was 1.73 dl/g. The copolymer is designated COP-10 in Tables 1 and 2.

-18-

Tubes were extruded with an outer diameter of 2.321 mm and a wall thickness of 0.209 mm which were used for the preparation of a capsule of 2.2 cm length to be filled with dry, micronized levonorgestrel and to be used in an in vitro release study at 37.5°C. Averaged over a time period of 90 days the release rate was found to be 14.2 µg/cm.day with a standard error of 0.51 µg/cm.day.

EXAMPLE 7:

A copolymer was prepared according to the procedure of Example 6 but utilizing a caprolactone solution composed of 75.0 g trimethylene carbonate in 425.6 g caprolactone. The conversion was better than 99.0% according to a weight loss of 0.97% at 220°C. The intrinsic viscosity in chloroform was 2.21 dl/g. The copolymer is designated COP-11 in Tables 1 and 2.

Two capsules were prepared of 2.5 cm length with an outer diameter of 2.630 mm and a wall thickness of 0.299 mm. The capsules, filled with 15.6 and 15.2 dry, micronized levonorgestrel exhibited in vitro release rates of 16.1 and 17.1 µg/cm.day with standard errors of 0.47 and 0.53 µg/cm.day, respectively, averaged over a time period of 90 days.

EXAMPLE 8:

A copolymer was prepared according to the procedure of Example 6 but utilizing a caprolactone solution composed of 102.5 g trimethylene carbonate in 409.0 g caprolactone. The conversion was better than 99.1% according to a weight loss of 0.83% at 220°C. The intrinsic viscosity in chloroform was 1.53 dl/g. The copolymer is designated COP-12 in Tables 1 and 2.

Two capsules were prepared of 2.7 cm length with an

-19-

outer diameter of 2.452 mm and a wall thickness of 0.249 mm. The capsules, filled with 15.3 and 18.8 mg dry, micronized levonorgestrel exhibited in vitro release rates of 28.0 and 27.4  $\mu\text{g}/\text{cm}\cdot\text{day}$  with standard errors of 1.00 and 0.98  $\mu\text{g}/\text{cm}\cdot\text{day}$ , respectively, averaged over a time period of 90 days.

While the invention has been described above with reference to specific examples and embodiments, it will be understood that the invention is not to be limited to specific examples and embodiments except as defined in the following claims.

-20-

Claims

1. A biodegradable reservoir device for sustained delivery of a drug contained therein, said device comprising a tubular wall of a random copolymer  
5 comprising trimethylene carbonate and caprolactone, said trimethylene carbonate being present in amounts of 5-25 mole-%.
2. The biodegradable article of Claim 1, further comprising a non-hydrophilic drug contained therein.
- 10 3. The device of Claim 2, wherein said drug is selected from the group consisting of contraceptive agents, hormones,, narcotic antagonists, antineoplastic agents, anti-inflammatory agents, and mixtures thereof.
4. The article of Claim 3, wherein said drug  
15 comprises levonorgestrel.
5. The article of Claim 1 where said random copolymer comprises 10-20 mole-% trimethylene carbonate.
6. The article of Claim 1 where said random copolymer has an intrinsic viscosity in chloroform in  
20 excess of 1.5 dl/g.
7. The article of Claim 1 which is filled with the drug in the form of a dry, micronized powder.
8. The article of Claim 1 which is filled with the drug in the form of a powder mixed with a suitable  
25 diluent or dispersing agent which remains in the sealed capsule.


-21-

9. The article of Claim 1 which is filled with the drug in the form of a powder mixed with a volatile diluent, said diluent being removed by evaporation prior to finally sealing the capsule.

5        10. An implantable pharmaceutical composition comprising an intimate mixture of a drug with a random copolymer of caprolactone and trimethylene carbonate in the compositional range of 5-25 mole% trimethylene carbonate content, said pharmaceutical composition being  
10      in cylindrical or spherical shape.

11. A pharmaceutical composition of Claim 10 where said random copolymer is in the compositional range of 10-20 mole-% trimethylene carbonate content.

1/1

*FIG. 1*



# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/02842

**I. CLASSIFICATION OF SUBJECT MATTER** (In several classification symbols apply, indicate all)<sup>1</sup>  
According to International Patent Classification (IPC) or to both National Classification and IPC  
IPC(5): A61K 9/64  
U.S.C1: 424/456

**II. FIELDS SEARCHED**  
Minimum Documentation Searched<sup>2</sup>  
Classification System Classification Symbols  
U.S. 424/426, 456, 486

Documentation Searched other than Minimum Documentation  
to the extent that such Documents are included in the Fields Searched<sup>3</sup>

**III. DOCUMENTS CONSIDERED TO BE RELEVANT**<sup>4</sup>  
Category<sup>5</sup> Citation of Document, with indication, where appropriate, of the relevant passages<sup>6</sup> Relevant to Claim No.<sup>7</sup>

Y	US, A, 4,148,871 (PITT) 10 April 1979; See entire document.	1-11
Y	US, A, 4,702,917 (SCHINDLER) 27 October 1987; See entire document.	1-11
Y	US, A, 4,863,472 (TORMALA) 05 September 1989; See Table 1.	1-11

• Special categories of cited documents:<sup>8</sup>  
"A" document defining the general state of the art which is not considered to be of particular relevance  
"E" earlier document but published on or after the international filing date  
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
"O" document referring to an oral disclosure, use, exhibition or other means  
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step  
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  
"Δ" document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search :

13 June 1991

International Searching Authority<sup>9</sup>

ISA/US

Date of Mailing of this International Search Report :

10 JUL 1991

Signature of Authorized Officer<sup>10</sup>

Raj Bawa

*R. Bawa*